1-deoxy-1-(ethylamino)-L-glucitol | 937021-77-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-deoxy-1-(ethylamino)-L-glucitol
• 英文别名: (2S,3S,4S,5R)-6-(ethylamino)hexane-1,2,3,4,5-pentol
• CAS: 937021-77-7
• 化学式: C₈H₁₉NO₅
• 分子量: 209.243
• InChiKey: IKXCHOUDIPZROZ-KVPKETBZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  113
• 氢给体数：
  6
• 氢受体数：
  6

文献信息

• USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER
  申请人：SURKOV Kirill Gennadievich

  公开号：US20100087399A1

  公开（公告）日：2010-04-08

  The present invention provides novel methods of combination therapy of ovarian cancer, pharmaceutical kits and combinations of 9-oxoacridine-10-acetic acid and/or salts and/or esters thereof with one or more chemotherapeutic agents. The proposed combination therapy is useful in enhancing the action of chemotherapeutic agents and their proliferative activity on human ovarian cancer cells.

  本发明提供了一种新的卵巢癌联合治疗方法，包括使用9-氧基喹啉-10-乙酸及/或其盐和/或酯与一种或多种化疗药物的药物组合和药物套件。所提出的联合治疗方法对于增强化疗药物的作用和其对人类卵巢癌细胞的增殖活性非常有用。
• Method for treatment of primary hormone resistant endometrial and breast cancers
  申请人：Lipoxen Technologies Limited

  公开号：US10406150B2

  公开（公告）日：2019-09-10

  The invention provides a method for treatment of primary progesterone receptor-negative (PR−) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (PR) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (ER−) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (SERM) or a selective estrogen receptor down-regulator (SERD). Also provided are compositions related to the above methods.

  本发明提供了一种治疗原发性孕酮受体阴性（PR-）子宫内膜癌的方法，包括给药(i)克利达莫或其盐或酯和(ii)孕酮受体（PR）激动剂。本发明进一步提供了一种治疗原发性雌激素受体阴性（ER-）乳腺癌的方法，包括给药(i)克利达莫或其盐或酯和(ii)选择性雌激素受体调节剂（SERM）或选择性雌激素受体下调调节剂（SERD）。还提供了与上述方法相关的组合物。
• METHOD FOR TREATMENT OF PRIMARY HORMONE RESISTANT ENDOMETRIAL AND BREAST CANCERS
  申请人：Lipoxen Technologies Limited

  公开号：EP3215137A1

  公开（公告）日：2017-09-13
• Method for Treatment of Primary Hormone Resistant Endometrial and Breast Cancers
  申请人：Lipoxen Technologies Limited

  公开号：US20170202827A1

  公开（公告）日：2017-07-20

  The invention provides a method for treatment of primary progesterone receptor-negative (PR−) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (PR) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (ER−) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (SERM) or a selective estrogen receptor down-regulator (SERD). Also provided are compositions related to the above methods.
• [EN] USE OF 9-OXOACRIDINE-10-ACETIC ACID, ITS SALTS AND ESTERS FOR ENHANCING THE EFFICACY OF ANTIANDROGENIC TREATMENT<br/>[FR] UTILISATION D'ACIDE 9-OXOACRIDINE-10-ACÉTIQUE, DE SELS ET D'ESTERS DE CELUI-CI POUR L'AMÉLIORATION DE L'EFFICACITÉ D'UN TRAITEMENT ANTIANDROGÉNIQUE
  申请人：SURKOV KIRILL GENNADIEVICH

  公开号：WO2008024027A2

  公开（公告）日：2008-02-28

  [EN] The present invention provides the use of 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salts and esters for the treatment of conditions for which decrease of androgen action is therapeutically favourable. Further, a pharmaceutical composition for decrease of androgen action is provided, comprising (a) 9-oxoacridine-10-acetic acid, its pharmaceutical acceptable salts or esters and (b) at least one antiandrogenic agent, as well as a method of treatment of conditions for which decrease of androgen action is therapeutically favorable, comprising the steps of: (a) administration of an effective amount of a compound selected from the group including 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salts and esters to a patient in need of such therapy and (b) hormonotherapy aimed at decrease of androgen action. Such conditions include but not limited to, alopecia, adenoma of prostate, prostate cancer and increased risk of prostate cancer relapse.
  [FR] La présente invention concerne l'utilisation d'acide 9-oxoacridine-10-acétique, de sels acceptables pharmaceutiquement et d'esters de celui-ci pour le traitement de troubles, pour lesquels une diminution de l'action androgène présente des effets favorables sur le plan thérapeutique. En outre, cette invention a pour objet une composition pharmaceutique qui est destinée à diminuer l'action androgène et renferme (a) de l'acide 9-oxoacridine-10-acétique, des sels acceptables pharmaceutiquement et des esters de celui-ci, et (b) au moins un agent antiandrogénique, ainsi qu'une méthode de traitement de troubles pour lesquels une diminution de l'action androgène présente des effets favorables sur le plan thérapeutique. Cette méthode consiste à (a) administrer, à un patient nécessitant un tel traitement, une quantité efficace d'un composé choisi parmi le groupe comprenant de l'acide 9-oxoacridine-10-acétique, des sels acceptables pharmaceutiquement et des esters de celui-ci, et (b) à prodiguer une hormonothérapie destinée à diminuer l'action androgène. Ces troubles comprennent notamment mais non seulement l'alopécie, l'adénome de la prostate, le cancer de la prostate et un risque accru de rechute d'un cancer de la prostate.